ArticleMayo Clinic proceedings2023
Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory.
Article in Mayo Clinic proceedings, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Hypertension Incidence and Blood Pressure Control in Hispanic or Latino Adults in the HCHS/SOL Study.JAMA network open · 2026Article
- Blood Pressure Outcomes Among US Veterans Initiating Hypertension Treatment, 2014 to 2023.Circulation. Population health and outcomes · 2026Article
- Bilateral Adrenal Primary Aldosteronism Is Uniformly Present in Hypertensive Afro-Caribbean First-Generation Immigrants to Western Canada.Journal of the American Heart Association · 2026Article
- Trends in Blood Pressure Control During the COVID-19 Pandemic: A Study of 17 US Health Systems in the National Patient-Centered Clinical Research Network Blood Pressure Control Laboratory.Journal of the American Heart Association · 2026Article
- Impact of COVID-19 Infection on Blood Pressure Variability and Cardiovascular Outcomes in Hypertensive Patients After Complete Liberalization of Epidemic Control in China.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Hypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID-19 Pandemic.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Lessons Learned From COVID-19: Never Lower the Guard in Promoting Hypertension Awareness.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Article
- Trends in Blood Pressure Control among US Adults With Hypertension, 2013-2014 to 2021-2023.American journal of hypertension · 2025Article
- Observational
- What Constitutes Adequate Control of High Blood Pressure? Current Considerations.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024Article
- Article
- Screening for hypertension in adults: protocol for evidence reviews to inform a Canadian Task Force on Preventive Health Care guideline update.Systematic reviews · 2024Article
- Racial Impact on Inpatient Stroke Quality of Care in Two Community Hospitals.Journal of clinical medicine · 2023Article
- Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients.Mayo Clinic proceedings · 2023Article
- Poorly Controlled Blood Pressure: The Virus and the Elephant.Mayo Clinic proceedings · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
30 authors.
Funding
Abstract
objectiveTo explore trends in blood pressure (BP) control before and during the COVID-19 pandemic. PATIENTS AND
methodsHealth systems participating in the National Patient-Centered Clinical Research Network (PCORnet) Blood Pressure Control Laboratory Surveillance System responded to data queries, producing 9 BP control metrics. Averages of the BP control metrics (weighted by numbers of observations in each health system) were calculated and compared between two 1-year measurement periods (January 1, 2019, through December 31, 2019, and January 1, 2020, through December 31, 2020).
resultsAmong 1,770,547 hypertensive persons in 2019, BP control to <140/<90 mm Hg varied across 24 health systems (range, 46%-74%). Reduced BP control occurred in most health systems with onset of the COVID-19 pandemic; the weighted average BP control was 60.5% in 2019 and 53.3% in 2020. Reductions were also evident for BP control to <130/<80 mm Hg (29.9% in 2019 and 25.4% in 2020) and improvement in BP (reduction of 10 mm Hg in systolic BP or achievement of systolic BP <140 mm Hg; 29.7% in 2019 and 23.8% in 2020). Two BP control process metrics exhibited pandemic-associated disruption: repeat visit in 4 weeks after a visit with uncontrolled hypertension (36.7% in 2019 and 31.7% in 2020) and prescription of fixed-dose combination medications among those with 2 or more drug classes (24.6% in 2019 and 21.5% in 2020).
conclusionBP control decreased substantially during the COVID-19 pandemic, with a corresponding reduction in follow-up health care visits among persons with uncontrolled hypertension. It is unclear whether the observed decline in BP control during the pandemic will contribute to future cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.